Targets › HSD17B13
2 programs from 2 companies in 2 trials: 2 Phase 2; Metabolic and endocrine, Gastroenterology; next expected readout Jan 2027.
Plays a pivotal role in hepatic lipid metabolism. In vitro, it catalyzes the oxidation of a variety of lipid substrates, including 17beta-estradiol, retinol, retinal, and leukotriene B4..; FUNCTION: [Isoform 2]: Has retinol/retinal dehydrogenase activity in vitro..; FUNCTION: [Isoform 1]: Does not have retinol/retinal dehydrogenase activity in vitro. (UniProt, Q7Z5P4)
Open in Phaseline: the race on HSD17B13, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Visirna Therapeutics HK | VSA006 siRNA targeting HSD17β13 mRNA to reduce HSD17β13 protein levels | HSD17B13 | Phase 2 | Nash | Jan 2027 |
| Regeneron Pharmaceuticals | ALN-HSD HSD17B13 inhibitor via RNA interference (gene silencing) | HSD17B13 | Phase 2 | Metabolic Dysfunction-Associated SteatoHepatitis (MASH) | Apr 2028 |
Metabolic Dysfunction-Associated SteatoHepatitis (MASH) (1) Nash (1)
small molecule (2)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.